News & Events

MimiVax to present results of SurVaxM immunotherapy in glioblastoma at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting

MimiVax to present results of SurVaxM immunotherapy in glioblastoma at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting

Clinical-stage biotechnology company also sharing its accomplishments to date and future plans at the 2019 Biotechnology Innovation Organization (BIO) International…
Roswell Park Research on Survivin Opens Up New Avenues for Cancer Immunotherapy

Roswell Park Research on Survivin Opens Up New Avenues for Cancer Immunotherapy

Molecule can exist on tumor surface, suggesting new opportunities for CAR T and antibody-based therapies BUFFALO, N.Y. — New research…
MimiVax awarded Orphan Drug Designation by US FDA for SurVaxM to treat glioblastoma patients

MimiVax awarded Orphan Drug Designation by US FDA for SurVaxM to treat glioblastoma patients

Novel immunotherapy, SurVaxM, being developed as treatment for glioblastoma BUFFALO, N.Y. — The U.S. Food and Drug Administration has awarded…
Clinical Trial Will Explore First-Time Use of SurVaxM Vaccine in Combination with REVLIMID® to Treat Rare Blood Cancer

Clinical Trial Will Explore First-Time Use of SurVaxM Vaccine in Combination with REVLIMID® to Treat Rare Blood Cancer

Immunotherapy Developed at Roswell Park Being Tested as Treatment for Multiple Myeloma BUFFALO, N.Y. — An immune-based therapy developed at…
Promising Vaccine Therapy for Glioblastoma Brain Cancers Moves on to Larger, Multisite Study

Promising Vaccine Therapy for Glioblastoma Brain Cancers Moves on to Larger, Multisite Study

Phase II clinical trial will assess efficacy of Roswell Park-developed immunotherapy in newly diagnosed patients BUFFALO, N.Y. — An innovative…
SurVaxM Phase I Completed

SurVaxM Phase I Completed

Phase I clinical trial results of SurVaxM presented at AACR Annual Meeting 2015 in Philadelphia BUFFALO, N.Y. — A first-of-its…